01 — At a Glance
The Company That Sold You Cough Syrup But Forgot to Taste It
- Q3 FY26 Revenue₹349 Cr
- Q3 FY26 PAT-₹10.7 Cr
- Q3 FY26 EPS-₹4.82
- TTM Revenue₹1,255 Cr
- TTM PAT-₹12.4 Cr
- Book Value / Share₹347
- Price to Book1.32x
- ROCE6.01%
- ROE (TTM)0.05%
- Debt/Equity0.51x
The Real Headline: Solara’s Q3 delivered ₹349 crore revenue — solid +16% YoY — but a ₹10.7 crore loss that somehow made CRISIL “revise the outlook to Stable.” The stock has returned -21% in 3 months, -28% in 6 months, and -19% in 5 years. The company lost ₹12.4 crores in TTM. And management just held a conference call admitting their entire ibuprofen business is “broken.” But let’s talk about “strategic optionality,” shall we?
02 — Introduction
An API Maker That Specializes in Making Losses Instead
Let me set the scene. You’re a pharmaceutical company. You need Active Pharmaceutical Ingredients — the actual medicine molecules that go into pills. You can’t make them yourself. So you call Solara. They’ve been making APIs since 2017, when they were spun out as a “pure play” from Strides Shasun. They own six globally compliant facilities. They sell to 73+ countries. On paper, they’re the Indian API player the industry has been waiting for.
Except — and this is becoming harder to ignore — Solara has lost money in more quarters than it has made it. TTM PAT is -₹12.4 crores. FY24 PAT was a catastrophic -₹567 crores. The stock peaked at ₹734 in early 2025 and has given back 37% since. The company has raised ₹450 crores through a rights issue, cut debt, and hired external advisors to “evaluate the ibuprofen business.” This is financial news speak for: “We have a big broken asset and we don’t know what to do with it.”
Here’s the thing: Solara makes two types of APIs. The “growth API” business (non-ibuprofen and derivatives) is reportedly “class-leading” with 56% gross margins and 25% EBITDA. But the plain ibuprofen business — which consumes manufacturing space, borrows capital, and drowns every quarter in red ink — is tanking the consolidated numbers. The Feb 2026 concall was management essentially admitting they have a “dated” process, 10,000+ tons of capacity for a 3,000-ton utilization, and big customers who won’t let them fix the technology because regulatory change is expensive. Welcome to business, but worse.
CRISIL Rating (Apr 2025): Revised outlook to Stable from Negative. Ratings at Crisil BBB/Stable (LT) and Crisil A3+ (ST). Translation: “We believe this is a temporary operational issue, not a solvency crisis. Proceed with cautious optimism, but don’t say we didn’t warn you if the advisor recommends selling the plant.”
03 — Business Model: APIs and Regrets
They Make the Molecules. Just Not Very Profitably.
Solara manufactures Active Pharmaceutical Ingredients — the actual drug compounds that get compressed into pills and sold to humans who hope they work. Their portfolio includes 60+ commercial APIs across anthelmintic (worm killer), anti-malaria, anti-infective, and NSAID (pain-killer) segments. The top 10 molecules contribute 84% of revenue. Translation: if one of your top 10 molecules is in trouble, you’re very much in trouble.
The business model sounds ideal: sell to global pharma companies at premium prices, avoid price wars through quality/regulatory compliance, maintain gross margins of 40-50%+ on the “good” APIs. Developed markets contribute 75% of sales. The company has DMF filings in the US and approvals from the USFDA, EU GMP, and Japan’s PMDA. All the right boxes are ticked.
But here’s where it breaks: plain ibuprofen is 45% of revenue (as per Feb 2026 management commentary). Plain ibuprofen has commodity pricing, low utilization due to capacity overhang, and regulatory lock-in that prevents modernization. Management stated they sell at 15-17% premium to competition but still can’t cover fixed costs at 3,000-ton utilization vs 10,000-ton capacity. The Pondicherry facility is “single-product” for ibuprofen. The Vizag facility (built for ibuprofen) is mothballed. Welcome to the cost structure that’s grinding them down.
Ibuprofen Revenue %~45%of total sales
Growth API Margin56%gross (ex-ibu)
Top 10 APIs84%of revenue
Global Reach73+ Countriesdeveloped: 75%
The Ibuprofen Trap, Explained for Your Grandma: Imagine you own a photocopier shop in 2005. You bought a huge machine for ₹50 lakhs. Everyone was copying documents back then. But then WhatsApp happened. Now you have a ₹50 lakh photocopier humming quietly in the corner, costing ₹5 lakhs a year to maintain, earning ₹2 lakhs in revenue. That’s Solara’s ibuprofen business — except the “customers won’t let you change the machine because regulatory paperwork is annoying.”
04 — Financials Overview: A Quarterly Horror Show
Q3 FY26: Loss So Polite, CRISIL Called It “Stable”
